CMDE005
/ Zhejiang Shimai Pharmaceutical
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
July 17, 2026
Phase I/IIa study of CMDE005, a novel masked EGFR-CD3 bispecific antibody, in advanced EGFR-positive solid tumors
(ESMO 2026)
- No abstract available
Bispecific • Metastases • P1/2 data • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1